Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of JNJ-79635322 with daratumumab with or without lenalidomide, or JNJ-79635322 with pomalidomide, in multiple myeloma
NL-OMON58883Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ramantamig in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Primary endpoint(s). Started Feb 2025; status: recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON58883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58883.